ARCH Venture Partners
ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Business Model:
Revenue: $90M
Employees: 11-50
Rankings
Detailed ARCH Venture Partners Information
Geographic Data
Address: 8725 W Higgins Rd
City: Chicago
State: IL
Zip: 60631
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$9B
Social
Linkedin
Crunchbase
Metrics
1,629,290Website Global Rank
14,535Website Monthly Traffic
Twitter Followers
Description
ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH has raised ten venture funds totaling over $3 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors.
Contact Phone:
+17733806600
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2022 | Proof Diagnostics | Series A | 45M |
| 7/2022 | Areteia Therapeutics | Series A | 0 |
| 12/2011 | Groove Biopharma | Series B | 6M |
| 6/2015 | Aledade | Series B | 30M |
| 5/2011 | Fate Therapeutics | Series B | 36M |
| 2/2020 | Volastra Therapeutics | Seed | 12M |
| 6/2015 | Twist Bioscience | Series C | 37M |
| 5/2021 | Interline Therapeutics | Series A | 59.5M |
| 7/2016 | Sienna Biopharmaceuticals | Series A | 12M |
| 4/2016 | Sienna Biopharmaceuticals | Series A | 34M |
| 8/2010 | Kilimanjaro Energy | Series A | 2.3M |
| 10/2018 | Lyell Immunopharma | Series A | - |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 4/2022 | Be Biopharma | Series B | 0 |
| 5/2015 | Denali Therapeutics | Series A | 217M |
| 5/2019 | Locanabio | Series A | 55M |
| 8/2022 | Sironax | Series B | 0 |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 3/2016 | Quanterix | Series D | 46M |
| 5/2000 | Alfalight | Series A | 6.1M |
| 8/2018 | Karuna Therapeutics | Series A | 0 |
| 7/2009 | Limerick BioPharma | Series C | 15M |
| 6/2018 | Biopalette | Seed Round | 5.2M |
| 9/2003 | INFICON | Post-IPO Equity | 15M |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 10/2013 | Genuity Science | Series A | 15M |
| 9/2011 | Siluria Technologies | Series B | 20M |
| 6/2008 | Limerick BioPharma | Venture Round | 15.2M |
| 2/2000 | Teach.com | Venture Round | 6M |
| 8/1999 | Teach.com | Venture Round | 4.6M |
| 11/2015 | Codiak Biosciences | Series A | 31M |
| 1/2015 | Hua Medicine | Series B | 0 |
| 12/2016 | ApoGen Biotechnologies | Series A | 7M |
| 1/2021 | Encodia | Series C | 75M |
| 3/2021 | OncoResponse | Series C | 0 |
| 10/2016 | Genomics Medicine Ireland | Series A | 40M |
| 11/2020 | Resilience | Series B | 0 |
| 1/2021 | Altos Labs | Series A | 3B |
| 12/2022 | Protillion Biosciences | Series A | 0 |
| 1/2023 | Akamis Bio | Debt Financing | 0 |
| 5/1995 | New Era of Networks | Series A | 2M |
| 1/2016 | Grail | Series A | 100M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 2/2002 | SilverStorm Technologies | Venture Round | 0 |
| 4/2021 | Volastra Therapeutics | Seed | 32M |
| 9/2018 | KSQ Therapeutics | Series C | 80M |
| 5/2002 | Impinj | Series F | 14M |
| 3/2015 | Semma Therapeutics | Series A | 44M |
| 7/2018 | AgBiome | Series C | 0 |
| 10/2020 | Walden Biosciences | Series A | 51M |
| 12/2002 | Idun Pharmaceuticals | Series A | 22.8M |
| 9/2004 | Nura | Series A | 9.5M |
| 8/2021 | Recuro Health | Series A | 0 |
| 7/2021 | Slingshot Biosciences | Series A | 0 |
| 12/2002 | Ceptyr | Venture Round | 20M |
| 7/2008 | Agios | Series A | 33M |
| 7/2018 | Nohla Therapeutics | Series B | 11M |
| 6/2017 | Arbor Biotechnologies | Series A | 15.6M |
| 6/2019 | Ultivue | Series C | 22M |
| 6/2022 | Vizgen | Series C | 0 |
| 6/2020 | Verve Therapeutics | Series A | 63M |
| 5/2019 | Verve Therapeutics | Series A | 58.5M |
| 10/2016 | Carrick Therapeutics | Series A | 95M |
| 11/2002 | NexCura | Series C | 4M |
| 1/2019 | Vir Biotechnology | Series B | 327.6M |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 5/2014 | Sorbent Therapeutics | Series D | 0 |
| 6/2011 | Sorbent Therapeutics | Series B | 0 |
| 1/2021 | Cytrellis Biosystems | Series C | 50M |
| 12/2013 | Juno Therapeutics | Series A | 120M |
| 10/2017 | KSQ Therapeutics | Series B | 76M |
| 3/2015 | Kura Oncology | Private Equity Round | 60M |
| 8/2002 | Ahura Scientific | Series A | 12.5M |
| 6/2018 | Cytrellis Biosystems | Series B | 0 |
| 8/2010 | Ciespace | Series A | 5M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 8/2015 | Agrivida | Series D | 10.7M |
| 7/2012 | Chiasma | Series D | 38.5M |
| 1/2012 | Semprius | Venture Round | 7.5M |
| 5/2003 | Fast Track | Series D | 0 |
| 11/2017 | AnchorDx | Series B | 28M |
| 11/2007 | BIND Therapeutics | Series B | 16M |
| 12/2000 | Alfalight | Series B | 28M |
| 9/2004 | Vascular Architects | Series E | 0 |
| 9/2015 | Just - Evotec Biologics | Series A | 15M |
| 3/2021 | Interline Therapeutics | Seed Round | 32.5M |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 1/2009 | Qwell Pharmaceuticals | Series A | 7M |
| 4/1998 | Apropos Technology | Series C | 16M |
| 1/2002 | NeurogesX | Series B | 22.9M |
| 7/2014 | Faraday Pharmaceuticals | Series A | - |
| 2/2023 | IngredientWerks | Seed Round | - |
| 5/2004 | Ensemble Therapeutics | Series A | 15M |
| 9/2000 | Impinj | Series A | 15M |
| 1/1992 | GenVec | Venture Round | - |
| 7/2019 | One BioMed | Series A | 5M |
| 2/2015 | Cytrellis Biosystems | Series A | 7.1M |
| 1/1994 | Eichrom Technologies | Venture Round | - |
| 12/2021 | ONI | Series B | 75M |
| 4/2021 | Ultivue | Series D | 50M |
| 9/2012 | Adesto Technologies | Series D | 14M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 10/2013 | Boreal Genomics | Series C | 0 |
| 7/2000 | LightCross, Inc. | Series A | 11.3M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 6/1996 | New Era of Networks | Series C | 7.5M |
| 10/2001 | Nanosys | Seed Round | 1.7M |
| 3/2007 | Surface Logix | Series D | 19.9M |
| 12/2002 | Amphora Discovery | Series B | 12.5M |
| 9/2008 | Sapphire Energy | Venture Round | 35M |
| 11/2009 | Receptos | Series A | 25M |
| 9/2010 | Sorbent Therapeutics | Series B | 0 |
| 5/2018 | LunaDNA | Venture Round | 0 |
| 7/2015 | Arivale | Series B | 36M |
| 8/2005 | Univa | Series A | 8M |
| 12/2013 | Bellerophon Therapeutics | Series A | 0 |
| 8/2007 | Accelerator Corp. | Series C | 22.5M |
| 9/2005 | KOTURA | Series B | 13M |
| 5/2009 | Lycera | Series A | 0 |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 1/1989 | Nanophase Technologies | Venture Round | - |
| 2/2008 | MediaPhy | Series A | 7M |
| 12/2011 | Permeon Biologics | Venture Round | 2.5M |
| 11/2019 | EGenesis | Series B | 0 |
| 6/2000 | NeurogesX | Series A | 8.4M |
| 7/2012 | Impinj | Debt | 21M |
| 7/2003 | Alnylam Pharmaceuticals | Private Equity Round | 24.6M |
| 4/2017 | Sienna Biopharmaceuticals | Series B | 0 |
| 11/2017 | Semma Therapeutics | Series B | 0 |
| 3/2017 | Grail | Series B | 0 |
| 10/2013 | SAGE Therapeutics | Series B | 20M |
| 2/2021 | Excision BioTherapeutics | Series A | - |
| 5/2008 | Univa | Series B | 0 |
| 6/2020 | JW Therapeutics | Series B | 0 |
| 1/2011 | Univa | Venture Round | 0 |
| 4/2001 | Fast Track | Series C | 0 |
| 8/1999 | Ceptyr | Venture Round | 11.5M |
| 9/2000 | Extreme Devices | Venture Round | 0 |
| 10/1999 | Intelligent Reasoning Systems | Venture Round | 7M |
| 10/2009 | Innovalight | Venture Round | 0 |
| 1/2005 | Ahura Scientific | Series B | 10M |
| 8/2011 | Shocking Technologies | Series C | 0 |
| 1/2002 | AmberWave | Series B | 25M |
| 6/2007 | Artificial Muscle Inc. | Series B | 20M |
| 2/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 8/2010 | Crystal IS | Venture Round | 4M |
| 11/2021 | Singleron Biotechnologies | Series B | 0 |
| 6/2009 | Semprius | Series B | 0 |
| 1/2005 | SilverStorm Technologies | Series A | 1.2M |
| 4/2020 | Erasca | Series B | 0 |
| 7/2016 | Hangzhou Just Biotherapeutics (Just China) | Series A | 14M |
| 8/2011 | Oncofactor | Series A | 2.1M |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 11/2017 | ImmusanT | Series C | 40M |
| 3/2004 | Reef Point Systems | Series D | 18M |
| 5/2021 | HiberCell | Series B | 0 |
| 10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
| 3/2006 | Theraclone Sciences | Series A | 0 |
| 5/2019 | LunaDNA | Venture Round | 4.6M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 12/2005 | NeurogesX | Series D | 20M |
| 4/2013 | Syros Pharmaceuticals | Series A | 30M |
| 9/2015 | Faraday Pharmaceuticals | Series A | 30M |
| 1/2021 | EQRx | Series B | 500M |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 1/2015 | UNITY Biotechnology | Series A | 2.3M |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 4/2012 | Sapphire Energy | Series C | 0 |
| 4/2005 | Ikaria | Series A | 10M |
| 10/2016 | UNITY Biotechnology | Series B | 116M |
| 3/2017 | Aledade | Series B | 40.2M |
| 9/1995 | New Era of Networks | Series B | 1.9M |
| 3/2012 | Receptos | Venture Round | 30M |
| 11/2002 | Surface Logix | Series C | 25M |
| 11/2005 | Nanosys | Series C | 0 |
| 3/2018 | UNITY Biotechnology | Series C | 55M |
| 8/2017 | UNITY Biotechnology | Series B | 35M |
| 5/2008 | Sapphire Energy | Series B | 50M |
| 3/2017 | EGenesis | Series A | 0 |
| 3/2007 | Ahura Scientific | Series B | 0 |
| 8/2003 | Xtera | Venture Round | 0 |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 12/2001 | R2 Technology | Venture Round | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 2/2008 | KOTURA | Series C | 0 |
| 5/2016 | OncoResponse | Series A | 0 |
| 7/2019 | Agrivida | Venture Round | 0 |
| 8/2017 | Hangzhou Just Biotherapeutics (Just China) | Series B | 59.6M |
| 2/2005 | Cambrios Technologies | Series B | 12M |
| 4/2007 | Shocking Technologies | Series A | 7M |
| 1/2018 | Gossamer Bio | Series A | 100M |
| 11/2016 | Nohla | Series A | 43.5M |
| 9/1999 | NexCura | Series A | 6M |
| 6/2004 | KOTURA | Series A | 11M |
| 12/1999 | ProjectGuides.com | Series A | - |
| 7/2018 | Omniome | Series B | 0 |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 8/2004 | Cambrios Technologies | Series A | 1.8M |
| 4/2007 | Cambrios Technologies | Series C | 18.5M |
| 11/2009 | Cambrios Technologies | Series D | 14.5M |
| 3/2004 | Artificial Muscle Inc. | Series A | 3.3M |
| 2/2014 | Twist Bioscience | Series A | 9.1M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 2/2023 | Slingshot Biosciences | Series A | 0 |
| 12/2020 | Locanabio | Series B | 0 |
| 3/2020 | Cero Therapeutics | Series A | 0 |
| 10/2015 | Aira Tech Corp. | Seed Round | 790k |
| 4/2021 | Vizgen | Series B | 0 |
| 5/2018 | Beam Therapeutics | Series A | 87M |
| 3/2016 | Aira | Series A | 2.5M |
| 3/2022 | Recuro Health | Convertible Note | - |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 6/2012 | Cooledge Lighting | Series A | 3.1M |
| 5/2012 | Newvem | Venture Round | 4M |
| 1/2011 | Acylin Therapeutics | Series A | 4.4M |
| 2/2010 | Shocking Technologies | Series B | 0 |
| 5/2020 | Mindstrong | Series C | 100M |
| 9/2022 | Orbital Therapeutics | Seed Round | - |
| 6/2021 | ImmuneID | Series A | 0 |
| 1/2007 | VBI Vaccines | Series A | 35.7M |
| 1/2018 | Scholar Rock | Series C | 47M |
| 1/2017 | Vir Biotechnology | Venture Round | 150M |
| 5/2004 | Ensemble Discovery | Series A | 15M |
| 11/2007 | Ensemble Discovery | Series B | 15M |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 2/2000 | Reef Point Systems | Venture Round | 22M |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 1/2018 | Ultivue | Series B | 20M |
| 10/2022 | Neumora Therapeutics | Series B | 0 |
| 4/2013 | Sorbent Therapeutics | Venture Round | 2.5M |
| 8/2022 | Vilya | Series A | 50M |
| 11/2021 | Generate Biomedicines | Series B | 0 |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 4/2023 | Recuro Health | Series B | 0 |
| 3/2023 | Rapport Therapeutics | Series A | 0 |
| 8/2008 | Quanterix | Series A | 15M |
| 7/2006 | AmberWave | Series E | 0 |
| 1/2003 | Vascular Architects | Series D | 0 |
| 1/2021 | LifeMine Therapeutics | Series B | 0 |
| 12/2022 | SonoThera | Series A | 0 |
| 6/2020 | bit.bio | Series A | 41.5M |
| 6/2018 | Mindstrong | Series B | 15M |
| 6/2017 | Mindstrong | Series A | 14M |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 6/2006 | Nitronex | Venture Round | 21.8M |
| 11/2022 | Human Immunology Biosciences | Series A | 0 |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 4/2010 | Achaogen | Series C | 56M |
| 3/2019 | Erasca | Series A | 0 |
| 10/2013 | NextCODE Health | Series A | 15M |
| 7/2012 | Cambrios Technologies | Venture Round | 3.9M |
| 4/2015 | Movidius | Series E | 0 |
| 2/2002 | INFICON | Post-IPO Equity | 0 |
| 9/2018 | OncoResponse | Series B | 40M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 7/2012 | Bluebird Bio | Series D | 0 |
| 11/2012 | Nanosys | Series E | 15M |
| 2/2015 | Chiasma | Series E | 70M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 8/2006 | Magen BioSciences | Series A | 15.4M |
| 11/2022 | hC Bioscience | Series A | 0 |
| 7/2011 | Adesto Technologies | Series C | 17.4M |
| 8/2009 | Shocking Technologies | Series B | 0 |
| 8/2014 | Juno Therapeutics | Series B | 134M |
| 10/2018 | Glympse Bio | Series A | 0 |
| 1/2016 | Codiak Biosciences | Series B | 61M |
| 7/2015 | Voxel8 | Series A | 12M |
| 3/2022 | Nutcracker Therapeutics | Series C | 167M |
| 9/2020 | Nutcracker Therapeutics | Series B | 60M |
| 12/2020 | SciNeuro | Series A | 100M |
| 9/2014 | Scholar Rock | Series A | 20M |
| 10/2019 | Prime Medicine | Series A | 115M |
| 4/2000 | eCustomers.com | Series B | 18M |
| 3/2007 | Ikaria | Series B | 280M |
| 8/2015 | AgBiome | Series B | 0 |
| 9/2020 | Dewpoint Therapeutics | Series B | 0 |
| 11/2006 | Chiasma | Series C | 44M |
| 6/2004 | AmberWave | Series D | 21M |
| 11/2001 | AmberWave | Venture Round | - |
| 10/2022 | Treeline Biosciences | Series A | 261.3M |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 1/2010 | Innovalight | Series D | 0 |
| 5/2006 | Innovalight | Series B | 0 |
| 10/2016 | BlackThorn Therapeutics | Series A | 40M |
| 1/2000 | ePolicy | Series A | 14M |
| 4/1999 | eCustomers.com | Seed Round | - |
| 12/2019 | Epirium Bio | Series A | 0 |
| 9/2012 | 908 Devices | Series A | 8.1M |
| 11/2003 | Medvantx | Series C | 5M |
| 9/2020 | Biopalette | Series A | 9.5M |
| 2/2002 | Accumedia | Series C | 2M |
| 6/2002 | Xenoport | Series B | 43.9M |
| 4/2000 | ProjectGuides.com | Series B | 6.3M |
| 9/2019 | Faraday Pharmaceuticals | Series B | 25M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 7/2004 | Impinj | Series C | 22M |
| 3/2022 | LifeMine Therapeutics | Series C | 0 |
| 4/2019 | Insitro | Series A | 100M |
| 5/2015 | 908 Devices | Series C | 11.6M |
| 6/2018 | Hangzhou Just Biotherapeutics (Just China) | Series B | 0 |
| 8/2022 | Homeward | Series B | 0 |
| 12/2002 | Alfalight | Series C | 15M |
| 6/2006 | VLST Corporation | Series B | 55M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 8/2012 | Sorbent Therapeutics | Series C | 18.1M |
| 9/2011 | Theraclone Sciences | Series B | 10.6M |
| 10/2007 | Innovalight | Series C | 0 |
| 2/2008 | PhaseRx | Series A | 20.2M |
| 1/2019 | Transcenta | Venture Round | - |
| 1/2020 | EQRx | Series A | 200M |
| 1/2013 | Siluria Technologies | Series C | 2.9M |
| 5/2017 | Aira Tech Corp. | Series B | 12M |
| 4/2013 | AgBiome | Series A | 17.5M |
| 1/2020 | Vizgen | Series A | 14M |
| 2/2002 | Nanosys | Series A | 15M |
| 10/2006 | Aveso | Series B | 6.3M |
| 2/2004 | NeurogesX | Series C | 35M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 2/2017 | Vividion Therapeutics | Series A | 50M |
| 4/2013 | TRELYS | Seed Round | 2.5M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 5/2018 | Brii Biosciences | Venture Round | 260M |
| 4/2016 | Hua Medicine | Series C | 0 |
| 5/2018 | CStone Pharmaceuticals | Series B | 260M |
| 10/2005 | Surface Logix | Venture Round | 32M |
| 3/2009 | Surface Logix | Series E | 15M |
| 1/2019 | Geneception | Series A | - |
| 7/2012 | Siluria Technologies | Series C | 30M |
| 11/2012 | Quanterix | Series C | 0 |
| 7/2018 | Qihan Biotech | Series A | 7.8M |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 1/2020 | Omniome | Series C | 60M |
| 10/2019 | Voxel8 | Series B | - |
| 8/2007 | Xtera | Venture Round | 52M |
| 2/2019 | HiberCell | Series A | 60.8M |
| 6/2018 | Metacrine | Series C | 65M |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 11/2011 | Agios | Series C | 78M |
| 9/2022 | Elephas | Series B | 41.5M |
| 3/2014 | SAGE Therapeutics | Series C | 38M |
| 1/2020 | Transcenta | Series B | 0 |
| 1/2000 | Illumina | Venture Round | 0 |
| 4/2011 | Bluebird Bio | Series C | 30M |
| 2/2007 | Omeros | Series E | 0 |
| 7/2007 | Semprius | Series A | 4.1M |
| 6/2011 | Semprius | Series C | 20M |
| 8/2006 | Crystal IS | Series B | 10.6M |
| 11/2009 | Fate Therapeutics | Series B | 30M |
| 5/2023 | OncoResponse | Venture Round | 0 |
| 3/2007 | Theraclone Sciences | Series B | 29M |
| 8/2015 | Metacrine | Series A | 36M |
| 11/2014 | AgBiome | Venture Round | 0 |
| 8/2002 | Midstream Technologies | Series C | 26M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 3/2001 | Midstream Technologies | Series B | 16M |
| 6/2015 | Pulmatrix | Post-IPO Equity | 10M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 3/2013 | Receptos | Series B | 30M |
| 3/2021 | EGenesis | Series C | 0 |
| 1/2016 | Scholar Rock | Series B | 36M |
| 12/2005 | Impinj | Series D | 26.5M |
| 11/2007 | Fate Therapeutics | Series A | 12M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 6/2010 | BIND Therapeutics | Series C | 12.4M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 10/2014 | Syros Pharmaceuticals | Series B | 53M |
| 2/2022 | Dewpoint Therapeutics | Series C | 0 |
| 5/2019 | LunaPBC | Venture Round | 4.6M |
| 10/2007 | Allozyne | Series B | 30M |
| 6/2010 | Adesto Technologies | Venture Round | 3.5M |
| 5/2008 | Adesto Technologies | Series A | 11.5M |
| 12/2005 | Allozyne | Series A | 3.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 3/2010 | Theraclone Sciences | Venture Round | 1.5M |
| 5/2005 | Medvantx | Series D | 10.5M |
| 2/2022 | hC Bioscience | Series A | 0 |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 1/2023 | Paradigm | Series A | 0 |
| 8/2015 | PRIME Coalition | Venture Round | - |
| 10/2006 | Achaogen | Series B | 26M |
| 4/2010 | Groove Biopharma | Series A | 3.9M |
| 9/2001 | Amphora Discovery | Series A | 35M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2021 | Treeline Biosciences | Series A | - |
| 4/2021 | Jaguar Gene Therapy | Series B | 0 |
| 2/2023 | Aera Therapeutics | Series A | - |
| 1/2016 | Lodo Therapeutics | Series A | 0 |
| 9/2022 | Pretzel Therapeutics | Series A | 0 |
| 7/2020 | Encoded Therapeutics | Series D | 0 |
| 10/2015 | Pioneer Square Labs | Series A | 0 |
| 3/2007 | Impinj | Series E | 19M |
| 9/2011 | Hua Medicine | Series A | 50M |
| 3/2018 | Hua Medicine | Series D | 0 |
| 1/2019 | Sana Biotechnology | Seed Round | - |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 10/2018 | Nebula Genomics | Series A | 0 |
| 10/2010 | Siluria Technologies | Series A | 13.3M |
| 4/2000 | Nimble Technology | Series B | 16M |
| 5/2000 | Appliant.com | Venture Round | 20M |
| 9/2016 | Agrivida | Series E | 20.4M |
| 3/2017 | 908 Devices | Series D | 20M |
| 2/2021 | ImmuneID | Venture Round | 17M |
| 5/2016 | Homology Medicines | Series A | 43.5M |
| 7/2021 | Prime Medicine | Series B | 200M |
| 5/2014 | Twist Bioscience | Series B | 26M |
| 4/2020 | ROME Therapeutics | Series A | 0 |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 3/2021 | Insitro | Series C | 400M |
| 11/2022 | FogPharma | Series D | 0 |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 3/2023 | Volastra Therapeutics | Series A | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2020 | Singleron Biotechnologies | Series A | 30M |
| 9/2015 | Hangzhou Just Biotherapeutics (Just China) | Series A | 15M |
| 7/2016 | Just - Evotec Biologics | Series A | 14M |
| 8/2016 | Denali Therapeutics | Series B | 130M |
| 9/2007 | Limerick BioPharma | Debt Financing | 5M |
| 2/2023 | Aera Therapeutics | Series B | 0 |
| 9/2022 | Rippl Care | Seed Round | 32M |
| 12/2022 | Carrick Therapeutics | Series C | 0 |
| 6/2020 | Sana Biotechnology | Series A | 700M |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 8/2022 | Happy Health | Series A | 60M |
| 1/2000 | Classmates.com | Series B | 11M |
| 12/2020 | Sesh | Seed Round | 3.5M |
| 9/2000 | Viathan Corporation | Venture Round | 17M |
| 6/2000 | ePolicy | Series B | 0 |
| 8/2013 | 908 Devices | Series B | 7M |
| 1/2016 | Petra Pharma | Series A | 48M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 10/2015 | Ultivue | Series A | 5.2M |
| 6/2007 | Sapphire Energy | Series A | 1M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 4/2023 | Recuro Health | Series B | 0 |
| 3/2023 | Rapport Therapeutics | Series A | 0 |
| 3/2023 | Volastra Therapeutics | Series A | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 2/2023 | Aera Therapeutics | Series B | 0 |
| 2/2023 | Aera Therapeutics | Series A | - |
| 2/2023 | IngredientWerks | Seed Round | - |
| 2/2023 | Slingshot Biosciences | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
